Ann: Director Appointment, page-27

Dr Philip Krause was the deputy director of CBER, the branch of the FDA which is going to be responsible for all Mesoblast’s regulatory approvals. Having him on board as a new Director for Mesoblast is a big asset for the company. Bravo to Mesoblast!

I may have confirmation bias towards Mesoblast, but I stop for a minute and think…. The shorter’s thesis is now torn up into shreds and any rational person can see it. Firstly there is Dr Eric Rose coming on board as CMO. And now Dr Philip Krause coming on board as a director. If Mesoblast had no hopes for regulatory approvals, do you think these two Dr’s with distinguished careers would be associating themselves with a company that has little or no prospects? Especially when they have worked so hard in their lives and put their reputation above everything else that they have done.